Publications

  1. Gammon BL, Jaramillo C, Riggan KA, Allyse M. Decisional regret in women receiving high risk or inconclusive prenatal cell-free DNA screening results. J Matern Fetal Neonatal Med. 2018 Oct 1; 1-7 Epub 2018 Oct 01
    View PubMed
  2. Allyse M. Practice Committee of the American Soceity for Reproductive Medicine. American Society for Reproductive Medicine position statement on uterus transplantation: a common opinion. Fertility and Sterility. 2018; 110(4):605.
  3. Stoll KA, Mackison A, Allyse MA, Michie M. Conflicts of interest in genetic counseling: persistent underlying questions. Genet Med 2018 Sep; 20 (9):1096-1097
    View PubMed
  4. Michie M, Allyse M, Stoll KA, Master Z. Weaponizing Hope: Sources of Hope, Unrealistic Optimism, and Denial. Am J Bioeth 2018 Sep; 18 (9):25-27
    View PubMed
  5. Allyse MA, Wick MJ. Noninvasive Prenatal Genetic Screening Using Cell-free DNA. JAMA. 2018 Aug 14; 320 (6):591-592
    View PubMed
  6. Gammon BL, Otto L, Wick M, Borowski K, Allyse M. Implementing Group Prenatal Counseling for Expanded Noninvasive Screening Options. J Genet Couns. 2018 Aug; 27 (4):894-901 Epub 2017 Dec 15
    View PubMed
  7. Allyse M. CRSPR/CAS 9 and Human Therapeutics The Clinical Chemist. July 2018; 64(8):1266-67.
  8. Allyse M, Rust L. Assessing Duty to Warn in Donated Embryos. Am J Bioeth. 2018 Jul; 18 (7):75-76
    View PubMed
  9. Allyse M. "Whole Again": Why Are Penile Transplants Less Controversial Than Uterine? Am J Bioeth. 2018 Jul; 18 (7):34-35
    View PubMed
  10. Michie M, Allyse M. Gene modification therapies: views of parents of people with Down syndrome. Genet Med. 2018 Jun 21 Epub 2018 June 21
    View PubMed
  11. Farrell RM, Allyse MA. Key Ethical Issues in Prenatal Genetics: An Overview. Obstet Gynecol Clin North Am. 2018 Mar; 45 (1):127-141 Epub 2017 Dec 09
    View PubMed
  12. Allyse MA, Robinson DH, Ferber MJ, Sharp RR. Direct-to-Consumer Testing 2.0: Emerging Models of Direct-to-Consumer Genetic Testing. Mayo Clin Proc. 2018 Jan; 93 (1):113-120
    View PubMed
  13. Allyse M, Sharp RR. Preparing for the Ethical Practice of Precision Medicine Scientific American Medicine.2017;
  14. Stoll KA, Mackison A, Allyse MA, Michie M. Conflicts of interest in genetic counseling: acknowledging and accepting. Genet Med 2017 Aug; 19 (8):864-866 Epub 2017 Jan 26
    View PubMed
  15. Allyse M, Wick MJ. What do the new American College of Medical Genetics and Genomics (ACMG) guidelines mean for the provision of non-invasive prenatal genetic screening? J Obstet Gynaecol. 2017 Aug; 37 (6):795-798 Epub 2017 Apr 01
    View PubMed
  16. Allyse M, Aypar U, Bonhomme N, Darilek S, Dougherty M, Farrell R, Grody W, Highsmith WE, Michie M, Nunes M, Otto L, Pabst R, Palomaki G, Runke C, Sharp RR, Skotko B, Stoll K, Wick M. Offering Prenatal Screening in the Age of Genomic Medicine: A Practical Guide. J Womens Health (Larchmt). 2017 Jul; 26 (7):755-761 Epub 2017 Apr 07
    View PubMed
  17. Mozersky J, Ravitsky V, Rapp R, Michie M, Chandrasekharan S, Allyse M. Toward an Ethically Sensitive Implementation of Noninvasive Prenatal Screening in the Global Context. Hastings Cent Rep. 2017 Mar; 47: (2)41-49.
    View PubMed
  18. Parham L, Michie M, Allyse M. Expanding Use of cfDNA Screening in Pregnancy: Current and Emerging Ethical, Legal, and Social Issues Current Genetic Medicine Reports.02/11/2017;
  19. Li G, Chandrasekharan S, Allyse M. "The Top Priority Is a Healthy Baby": Narratives of Health, Disability, and Abortion in Online Pregnancy Forum Discussions in the US and China. J Genet Couns. 2017 Feb; 26 (1):32-39 Epub 2016 June 09
    View PubMed
  20. Tilburt JC, Allyse M, Hafferty FW. The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work? AMA J Ethics. 2017 Feb 01; 19 (2):199-206
    View PubMed
  21. Allyse M, Evans JP, Michie M. Dr. Pangloss's Clinic: Prenatal Whole Genome Sequencing and a Return to Reality. Am J Bioeth 2017 Jan; 17 (1):21-23
    View PubMed
  22. Allyse M, Hafferty F, Tilburt J. Sanctioning Oz (Almost): Quandaries and Ironies In the Ethics of Professional Self-Regulation. AMA Journal of Ethics.2016;().
  23. Floyd E, Allyse MA, Michie M. Spanish- and English-Speaking Pregnant Women's Views on cfDNA and Other Prenatal Screening: Practical and Ethical Reflections. J Genet Couns. 2016 Oct; 25 (5):965-77 Epub 2016 Jan 07
    View PubMed
  24. Meredith S, Kaposy C, Miller VJ, Allyse M, Chandrasekharan S, Michie M, Prenatal Testing PAG Coalition. Impact of the increased adoption of prenatal cfDNA screening on non-profit patient advocacy organizations in the United States. Prenat Diagn. 2016 Aug; 36 (8):714-9 Epub 2016 July 18
    View PubMed
  25. Michie M, Kraft SA, Minear MA, Ryan RR, Allyse MA. Informed decision-making about prenatal cfDNA screening: An assessment of written materials. Ethics Med Public Health. 2016 Jul-Sep; 2 (3):362-371 Epub 2016 Sept 13
    View PubMed
  26. Gammon BL, Kraft SA, Michie M, Allyse M. "I think we've got too many tests!": Prenatal providers' reflections on ethical and clinical challenges in the practice integration of cell-free DNA screening. Ethics Med Public Health. 2016 Jul-Sep; 2 (3):334-342
    View PubMed
  27. Li G., Allyse M. Experiences of Mandarin-speaking and English-speaking women of undergoing non-invasive prenatal genetic screening. Ethics, Medicine and Public Health.2016;2:(3):372-82.
  28. Steinbach RJ, Allyse M, Michie M, Liu EY, Cho MK. "This lifetime commitment": Public conceptions of disability and noninvasive prenatal genetic screening. Am J Med Genet A. 2016 Feb; 170A (2):363-374 Epub 2015 Nov 14
    View PubMed
  29. Michie M, Allyse M. Old Questions, New Paradigms: Ethical, Legal and Social Complications of Non-Invasive Prenatal Testing. AJOB Empirical Bioethics. 2015; 6(1).
  30. Allyse M, Sayres LC, Michie M, Goodspeed T, Cho M. Don't want no risk, don't want no problems: Public understandings of the risks and benefits of novel prenatal technologies in the United States. AJOB Empirical Bioethics.2015;6:(1):5-20.
    View PubMed
  31. Minear MA, Alessi S, Allyse M, Michie M, Chandrasekharan S. Noninvasive Prenatal Genetic Testing: Current and Emerging Ethical, Legal, and Social Issues. Annu Rev Genomics Hum Genet. 2015; 16:369-98.
    View PubMed
  32. Sayres LC, Allyse M, Goodspeed T, Cho MK. Demographic and Experiential Predictors of Public Attitudes towards Cell-Free Fetal DNA Journal of Genetic Counseling.0;23:(6):957-67.
    View PubMed
  33. Chandresekharan S, Minear M, Hung A, Allyse M. Noninvasive prenatal testing goes global. Science Translational Medicine.2014;
  34. Allyse M, Sayres LC, Goodspeed T, Cho MK. Attitudes Towards Non-Invasive Prenatal Testing Among US Adults of Reproductive Age Journal of Perinatology. 2014 March 6.
  35. Allyse M, Minear M, Berson E, Rote M, Sidhar S, Hung A, Chandresekharan S. Non-Invasive Prenatal Testing: A review of international implementation and challenges International Journal of Women's Health. 2014.
  36. Constantine M, Allyse M, Wall M, De Vries R, Rockwood TH. Imperfect Informed Consent in Non-Invasive Prenatal Testing: Lessons from the quad screen. Clinical Ethics.2013;
  37. Berryessa C, Martinex-Martin N, Allyse M. Ethical, Legal and Social Issues Surrounding Research on Genetic Contributions to Anti-Social Behavior Aggression and Violent Behavior.2013;605-610.
  38. Allyse M, Scott C. Too much of a good thing Nature Biotech. 2013:597-598.
  39. Allyse M, Sayres LC, Havard M, Norton ME, Hudgins L, Taylor J, King JS, Cho MK, Greely HT, Magnus D, Ormond KE. Best Practices in the Provision of Non-Invasive Prenatal Diagnosis Prenatal Diagnosis. 2013:656-61.
  40. Allyse M, Michie M. Not-so-incidental-findings: the ACMG recommendations on the reporting of incidental findings in clinical whole genome and whole exome sequencing Trends in Biotechnology. 2013:439-41.
  41. Allyse M. 23andMe, We and You: Direct-to-consumer genetics, intellectual property and informed consent Trends in Biotechnology. 2013:68-69.
  42. Goodspeed T, Allyse M, Sayres L, Norton ME, Cho MK. Translating Cell-Free Fetal DNA Trends in Biotechnology.2013;7-9.
  43. Allyse M, Sayres L, Norton M, King JS, Cho MK. Cell-free fetal DNA testing for fetal aneuploidy and beyond: Clinical integration challenges in the United States context Human Reproduction. 2012:3123-3131.
  44. Sayres LC, Allyse M, Goodspeed T, Cho MK. In the public interest? Consequences of broad patenting and restrictive licensing for cell-free fetal DNA testing Science Translational Medicine.2012;
  45. Sayres LC, Allyse M, Cho MK. Integrating stakeholder perspectives into the translation of cell-free fetal DNA testing for aneuploidy. Genome Medicine.2012;49.
  46. Tobin SL, Cho MK, Lee SSJ, Magnus D, Allyse M, Ormond KE, Garrison N. Customers or Research Participants? Guidance for Research Practices in Commercialization of Personal Genomics Genetics in Medicine. 2012:833-835.
  47. Allyse M, Karkazis K, Lee SSJ, Tobin SL, Greely HT, Cho MK, Magnus D. Informational Risk, Institutional Review, and Autonomy in the Proposed Changes to the Common Rule IRB: Ethics & Human Research. 2012.
  48. Sayres LC, Allyse M, Norton ME, Cho MK. Cell-free fetal DNA testing: a pilot study of obstetric healthcare provider attitudes toward clinical implementation Prenat Diagnosis.2011;1070-6.
  49. Allyse M, Milner LC, Cho MK. Ethics watch: the G.I. genome: ethical implications of genome sequencing in the military Nature Reviews Genetics. 2011; Ethics watch:589.
  50. Allyse M. Embryos, Ethics and Expertise: the emerging model of the scientific research ethics regulator Science and Public Policy. 2010:597-610.